Meeting
2014 ASCO Annual Meeting
Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status.
Authors
Jun Zhang
Winship Cancer Institute of Emory University, Atlanta, GA
Jun Zhang , Dongsheng Wang , Guoqing Qian , Fakeng Liu , Mohammad Aminur Rahman , Sreevinas Nannapaneni , Xu Wang , Xianghong Peng , Zhuo Georgia Chen , Kwok-Kin Wong , Fadlo Raja Khuri , Wei Zhou , Dong Moon Shin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Pharmacology
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2589)
DOI
10.1200/jco.2014.32.15_suppl.2589
Abstract #
2589
Poster Bd #
52
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Differential expression of LKB1, PD-L1, and PD-L2 in KRAS-mutant non-small cell lung cancer in never-smokers.
First Author: Antonio Calles
Poster
2019 ASCO Annual Meeting
S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
First Author: Shirish M. Gadgeel
First Author: Amanda J. Redig
Poster
2013 ASCO Annual Meeting
Genetic and molecular biomarker characterization of KRAS mutant non-small cell lung carcinoma (NSCLC) tumors.
First Author: Li Liu